Patent · US Active

Oral dosing of GLP-1 compounds

US10278923B2 · kind B2 · utility

20Cited by

1References

23Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Flemming S. Nielsen · Roskilde, DK
Per Sauerberg · Copenhagen, DK

Key dates

Filing date	Jul 17, 2017
Grant date	May 7, 2019
Priority date	—
Expiry date	Jul 17, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P3/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.